ONCOPHAGY SIGNED
Novel Atg4B-inhibitors and dual [Atg4B-carbonic anhydrase]inhibitors for interfering with cytoprotective mechanisms of cancercells in the acidic tumor micro-environment.
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0ONCOPHAGY project word cloud
Explore the words cloud of the ONCOPHAGY project. It provides you a very rough idea of what is the project "ONCOPHAGY" about.
Project "ONCOPHAGY" data sheet
The following table provides information about the project.
| Coordinator |
UNIVERSITEIT ANTWERPEN
Organization address contact info |
| Coordinator Country | Belgium [BE] |
| Total cost | 160˙800 € |
| EC max contribution | 160˙800 € (100%) |
| Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
| Code Call | H2020-MSCA-IF-2016 |
| Funding Scheme | MSCA-IF-EF-ST |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-05-01 to 2019-04-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | UNIVERSITEIT ANTWERPEN | BE (ANTWERPEN) | coordinator | 160˙800.00 |
Map
Project objective
The microenvironment of most solid tumors tends to be significantly more acidic than healthy tissue. Inadequate perfusion, oxygen limitation and cell metabolic changes, are key causative factors for this situation. The acidic pH induces a number of specific genetic, transcriptional and metabolic effects in tumor cells. These are required for survival under increased H-stress. Evidence is now mounting that these effects also play a major role in tumor progression, invasiveness and the development of multi-resistance to therapy. Two pivotal adaptations related to maintaining intracellular pH homeostasis in an acidic environment, have recently received significant attention: (1) the presence of chronic autophagy in tumors and (2) the overexpression of carbonic anhydrases (CAs), mainly CA IX and CA XII. This project will biopharmaceutically optimize a novel class of specific autophagy inhibitors that target Atg4B. The specific goal of this part of the project is to obtain orally bioavailable and metabolically stable compounds that are fit for in vivo applications. The relevance of these compounds is clear, given the unmet demand for reliable, specific inhibitors in the domain of autophagy. At the same time, the project will evaluate the potential for therapy development of the compounds in the framework of cancer. Finally, the proposal will explore whether a further increase of anti-tumor efficiency can be obtained by combining Atg4B- and CA-inhibitor pharmacophores in a single compound.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2019 |
Muhammet Tanc, Matthias Cleenewerck, Ammar Kurdi, Ria Roelandt, Wim Declercq, Guido De Meyer, Koen Augustyns, Wim Martinet, Pieter Van der Veken Synthesis and evaluation of novel benzotropolones as Atg4B inhibiting autophagy blockers published pages: 163-168, ISSN: 0045-2068, DOI: 10.1016/j.bioorg.2019.03.021 |
Bioorganic Chemistry 87 | 2019-08-05 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCOPHAGY" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ONCOPHAGY" are provided by the European Opendata Portal: CORDIS opendata.